Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Brain ; 145(9): 3250-3263, 2022 09 14.
Artigo em Inglês | MEDLINE | ID: mdl-35775424

RESUMO

ADNP and POGZ are two top-ranking risk factors for autism spectrum disorder and intellectual disability, but how they are linked to these neurodevelopmental disorders is largely unknown. Both ADNP and POGZ are chromatin regulators, which could profoundly affect gene transcription and cellular function in the brain. Using post-mortem tissue from patients with autism spectrum disorder, we found diminished expression of ADNP and POGZ in the prefrontal cortex, a region highly implicated in neurodevelopmental disorders. To understand the functional role of these neurodevelopmental disorder risk factors, we used viral-based gene transfer to investigate how Adnp or Pogz deficiency in mouse prefrontal cortex affects behavioural, transcriptomic and synaptic function. Mice with prefrontal cortex deficiency of Adnp or Pogz exhibited specific impairment of cognitive task performance. RNA-sequencing revealed that Adnp or Pogz deficiency induced prominent upregulation of overlapping genes enriched in neuroinflammation, similar to the elevation of pro-inflammatory genes in humans with neurodevelopmental disorders. Concomitantly, Adnp or Pogz deficiency led to the significant increase of pro-phagocytic microglial activation in prefrontal cortex, as well as the significant decrease of glutamatergic transmission and postsynaptic protein expression. These findings have uncovered the convergent functions of two top risk factors for autism spectrum disorder and intellectual disability in prefrontal cortex, providing a mechanism linking chromatin, transcriptional and synaptic dysregulation to cognitive deficits associated with neurodevelopmental disorders.


Assuntos
Transtorno do Espectro Autista , Proteínas de Ciclo Celular , Proteínas de Ligação a DNA , Proteínas de Homeodomínio , Deficiência Intelectual , Proteínas do Tecido Nervoso , Transtornos do Neurodesenvolvimento , Animais , Transtorno do Espectro Autista/genética , Proteínas de Ciclo Celular/genética , Cromatina , Proteínas de Ligação a DNA/genética , Proteínas de Homeodomínio/genética , Humanos , Deficiência Intelectual/complicações , Deficiência Intelectual/genética , Camundongos , Proteínas do Tecido Nervoso/genética , Transtornos do Neurodesenvolvimento/metabolismo , Fatores de Risco , Transposases/genética , Transposases/metabolismo
2.
Neuropharmacology ; 204: 108893, 2022 02 15.
Artigo em Inglês | MEDLINE | ID: mdl-34822816

RESUMO

Microduplication of the human 16p11.2 gene locus is associated with a range of neurodevelopmental outcomes, including autism spectrum disorder (ASD). Mice carrying heterozygous 16p11.2 duplication (16p11.2dp/+) display social deficits, which is attributable to impaired GABAergic synaptic function in prefrontal cortex (PFC) driven by downregulation of Npas4, an activity-dependent transcription factor that regulates GABA synapse formation. However, the molecular mechanisms underlying the diminished transcription of Npas4 in 16p11.2 duplication remain unknown. Npas4 is one of the target genes regulated by histone deacetylase 5 (HDAC5), an epigenetic enzyme repressing gene expression via removal of transcription-permissive acetyl groups from histones. Here we report that HDAC5 expression is elevated and histone acetylation is reduced at the Npas4 promoter in PFC of 16p11.2dp/+ mice. Treatment with the HDAC5 inhibitor LMK235 normalizes histone acetylation, restores GABAergic signaling in PFC, and significantly improves social preference in 16p11.2dp/+ mice. These findings suggest that HDAC5 inhibition is a promising therapeutic avenue to alleviate genetic, synaptic and behavioral deficits in 16p11.2 duplication conditions.


Assuntos
Transtorno Autístico/tratamento farmacológico , Transtorno Autístico/genética , Benzamidas/farmacologia , Benzamidas/uso terapêutico , Transtornos Cromossômicos/tratamento farmacológico , Transtornos Cromossômicos/genética , Histona Desacetilases/efeitos dos fármacos , Histona Desacetilases/fisiologia , Deficiência Intelectual/tratamento farmacológico , Deficiência Intelectual/genética , Acetilação/efeitos dos fármacos , Animais , Fatores de Transcrição Hélice-Alça-Hélice Básicos/genética , Fatores de Transcrição Hélice-Alça-Hélice Básicos/metabolismo , Deleção Cromossômica , Cromossomos Humanos Par 16/genética , Modelos Animais de Doenças , Regulação para Baixo , Expressão Gênica , Regulação Enzimológica da Expressão Gênica , Histona Desacetilases/genética , Histona Desacetilases/metabolismo , Histonas/metabolismo , Humanos , Camundongos Transgênicos
3.
Cell Rep ; 34(12): 108874, 2021 03 23.
Artigo em Inglês | MEDLINE | ID: mdl-33761364

RESUMO

Exposure to prolonged stress in critical developmental periods induces heightened vulnerability to psychiatric disorders, which may have sex-specific consequences. Here we investigate the neuronal circuits mediating behavioral changes in mice after chronic adolescent social isolation stress. Escalated aggression is exhibited in stressed males, while social withdrawal is shown in stressed females. In vivo multichannel recordings of free-moving animals indicate that pyramidal neurons in prefrontal cortex (PFC) from stressed males exhibit the significantly decreased spike activity during aggressive attacks, while PFC pyramidal neurons from stressed females show a blunted increase of discharge rates during sociability tests. Chemogenetic and electrophysiological evidence shows that PFC hypofunctioning and BLA principal neuron hyperactivity contribute to the elevated aggression in stressed males, while PFC hypofunctioning and VTA dopamine neuron hypoactivity contribute to the diminished sociability in stressed females. These results establish a framework for understanding the circuit and physiological mechanisms underlying sex-specific divergent effects of stress.


Assuntos
Rede Nervosa/fisiopatologia , Caracteres Sexuais , Isolamento Social/psicologia , Estresse Psicológico/fisiopatologia , Agressão , Tonsila do Cerebelo/fisiopatologia , Animais , Doença Crônica , Neurônios Dopaminérgicos/patologia , Feminino , Masculino , Camundongos Endogâmicos C57BL , Modelos Biológicos , Córtex Pré-Frontal/fisiopatologia , Células Piramidais/patologia , Área Tegmentar Ventral/fisiopatologia
4.
Transl Psychiatry ; 11(1): 99, 2021 02 04.
Artigo em Inglês | MEDLINE | ID: mdl-33542189

RESUMO

Autism spectrum disorder (ASD) is a lifelong developmental disorder characterized by social deficits and other behavioral abnormalities. Dysregulation of epigenetic processes, such as histone modifications and chromatin remodeling, have been implicated in ASD pathology, and provides a promising therapeutic target for ASD. Haploinsufficiency of the SHANK3 gene is causally linked to ASD, so adult (3-5 months old) Shank3-deficient male mice were used in this drug discovery study. We found that combined administration of the class I histone deacetylase inhibitor Romidepsin and the histone demethylase LSD1 inhibitor GSK-LSD1 persistently ameliorated the autism-like social preference deficits, while each individual drug alone was largely ineffective. Another behavioral abnormality in adult Shank3-deficient male mice, heightened aggression, was also alleviated by administration of the dual drugs. Furthermore, Romidepsin/GSK-LSD1 treatment significantly increased transcriptional levels of NMDA receptor subunits in prefrontal cortex (PFC) of adult Shank3-deficient mice, resulting in elevated synaptic expression of NMDA receptors and the restoration of NMDAR synaptic function in PFC pyramidal neurons. These results have offered a novel pharmacological intervention strategy for ASD beyond early developmental periods.


Assuntos
Transtorno do Espectro Autista , Histonas , Animais , Transtorno do Espectro Autista/tratamento farmacológico , Transtorno do Espectro Autista/genética , Modelos Animais de Doenças , Masculino , Camundongos , Proteínas dos Microfilamentos , Proteínas do Tecido Nervoso/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA